TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacological Intervention Project (Fluoxetine)
Brief Summary: This is a large scale study involving fluoxetine (Prozac) versus a placebo in the treatment of adolescents with alcohol use disorder (AUD) and major depression (MDD). All individuals will receive treatment for 12 weeks with a followup phase lasting 9 months.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): Fluoxetine
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine (Prozac) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus Treatment As Usual | Intervention Type: DRUG; Name: fluoxetine (Prozac); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo plus Treatment As Usual; Assigned to Arm(s): 2
C: Arm Label: Desvenlafaxine Succinate Sustained-Release; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Intervention Type: DRUG; Name: DVS SR; Assigned to Arm(s): Desvenlafaxine Succinate Sustained-Release
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: Duloxetine 60 mg; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: Duloxetine 30 mg; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): Duloxetine 30 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacological Intervention Project (Fluoxetine)
Brief Summary: This is a large scale study involving fluoxetine (Prozac) versus a placebo in the treatment of adolescents with alcohol use disorder (AUD) and major depression (MDD). All individuals will receive treatment for 12 weeks with a followup phase lasting 9 months.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine (Prozac) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus Treatment As Usual | Intervention Type: DRUG; Name: fluoxetine (Prozac); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo plus Treatment As Usual; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Intervention Type: BEHAVIORAL; Name: Multifamily Psychoeducation Group (MFPG); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Treatment as usual (TAU); Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy Of Gabapentin In The Management Of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
Brief Summary: RATIONALE: Gabapentin may be effective in relieving pain and other symptoms of peripheral neuropathy. It is not yet known if gabapentin is effective in treating peripheral neuropathy in cancer patients undergoing chemotherapy.

PURPOSE: Randomized phase III trial to determine the effectiveness of gabapentin in treating pain and other symptoms of peripheral neuropathy in cancer patients undergoing chemotherapy.


Options:
A: Arm Label: gabapentin; Type: EXPERIMENTAL; Interventions: Drug: gabapentin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): gabapentin | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Sham-laser acupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham-laser acupuncture | Arm Label: gabapentine; Type: ACTIVE_COMPARATOR; Interventions: Drug: gabapentine | Arm Label: Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture | Intervention Type: DEVICE; Name: Sham-laser acupuncture; Assigned to Arm(s): Sham-laser acupuncture | Intervention Type: DRUG; Name: gabapentine; Assigned to Arm(s): gabapentine | Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): Acupuncture
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin Extended Release tablets | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gabapentin Extended Release tablets; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Open Label; Type: N/A; Interventions: N/A | Arm Label: Open label; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma
Brief Summary: The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.


Options:
A: Arm Label: CAT-354 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 1mg/kg | Arm Label: CAT-354 5 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 5 mg/kg | Arm Label: CAT-354 10mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 10mg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 1mg/kg; Assigned to Arm(s): CAT-354 1 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 5 mg/kg; Assigned to Arm(s): CAT-354 5 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 10mg/kg; Assigned to Arm(s): CAT-354 10mg/kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab (MILR1444A) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab (MILR1444A); Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): N/A
D: Arm Label: Benralizumab (Medi-563); Type: EXPERIMENTAL; Interventions: Drug: Benralizumab (Medi-563) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benralizumab (Medi-563); Assigned to Arm(s): Benralizumab (Medi-563) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma
Brief Summary: The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.


Options:
A: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Benralizumab 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 0.3 mg/kg, Benralizumab 1.0 mg/kg
D: Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Tial Of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) As First-Line Therapy For Locally Recurrent or Metastatic Breast Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known whether paclitaxel works better with or without bevacizumab in treating breast cancer.

PURPOSE: This randomized phase III trial is to see if paclitaxel works better with or without bevacizumab in treating patients who have locally recurrent or metastatic breast cancer.


Options:
A: Arm Label: Bevacizumab for ROP; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: Conventional Laser for ROP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Laser for ROP | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab for ROP | Intervention Type: PROCEDURE; Name: Conventional Laser for ROP; Assigned to Arm(s): Conventional Laser for ROP
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
D: Arm Label: Paclitaxel + Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab, Drug: Paclitaxel | Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel, Paclitaxel + Bevacizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chiropractic Care, Medication, and Self-Care for Neck Pain
Brief Summary: This study will compare the effectiveness of chiropractic care, medications, and self-care on neck pain, a very common condition. The broad, long-term objective of this study is to identify effective therapies for neck pain sufferers and to increase understanding of neck pain conditions.


Options:
A: Intervention Type: PROCEDURE; Name: Chiropractic spinal manipulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Non-Steroidal anti-inflammatory drugs (NSAIDS); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tylenol with codeine; Assigned to Arm(s): N/A
B: Arm Label: 9 months of chiropractic care and exercise; Type: EXPERIMENTAL; Interventions: Other: chiropractic, Behavioral: exercise | Arm Label: 3 months of chiropractic care and exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: chiropractic, Behavioral: exercise | Intervention Type: OTHER; Name: chiropractic; Assigned to Arm(s): 3 months of chiropractic care and exercise, 9 months of chiropractic care and exercise | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): 3 months of chiropractic care and exercise, 9 months of chiropractic care and exercise
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Chiropractic Manual treatment + home exercise ( procedure+behavior) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Supervised rehabilitative exercise + home exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home exercise | Intervention Type: PROCEDURE; Name: Chiropractic Manual treatment + home exercise ( procedure+behavior); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Supervised rehabilitative exercise + home exercise; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Home exercise; Assigned to Arm(s): 3
D: Intervention Type: PROCEDURE; Name: Usual Care provided by a medical doctor (GP or Neurologist); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Usual care plus Physio-/ Manual Therapy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chiropractic Care, Medication, and Self-Care for Neck Pain
Brief Summary: This study will compare the effectiveness of chiropractic care, medications, and self-care on neck pain, a very common condition. The broad, long-term objective of this study is to identify effective therapies for neck pain sufferers and to increase understanding of neck pain conditions.


Options:
A: Intervention Type: PROCEDURE; Name: Chiropractic spinal manipulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Non-Steroidal anti-inflammatory drugs (NSAIDS); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tylenol with codeine; Assigned to Arm(s): N/A
B: Arm Label: Cognitive and physical program; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive, Relaxation, Exercise Therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive, Relaxation, Exercise Therapy; Assigned to Arm(s): Cognitive and physical program
C: Arm Label: Specific resistance training; Type: ACTIVE_COMPARATOR; Interventions: Other: Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck; Assigned to Arm(s): Specific resistance training
D: Intervention Type: BEHAVIORAL; Name: Behavioral treatments; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Physical therapy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chiropractic Care, Medication, and Self-Care for Neck Pain
Brief Summary: This study will compare the effectiveness of chiropractic care, medications, and self-care on neck pain, a very common condition. The broad, long-term objective of this study is to identify effective therapies for neck pain sufferers and to increase understanding of neck pain conditions.


Options:
A: Intervention Type: PROCEDURE; Name: Chiropractic spinal manipulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Non-Steroidal anti-inflammatory drugs (NSAIDS); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tylenol with codeine; Assigned to Arm(s): N/A
B: Arm Label: 1 hr training 50% supervision; Type: EXPERIMENTAL; Interventions: Behavioral: physical training exercise | Arm Label: 3 x 20 min training 50% supervision; Type: EXPERIMENTAL; Interventions: Behavioral: physical training exercise | Arm Label: 3 x 20 min training initial instructions; Type: EXPERIMENTAL; Interventions: Behavioral: physical training exercise | Arm Label: 10 x 6 min training 50% supervision; Type: EXPERIMENTAL; Interventions: Behavioral: physical training exercise | Arm Label: reference; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: physical training exercise; Assigned to Arm(s): 1 hr training 50% supervision, 10 x 6 min training 50% supervision, 3 x 20 min training 50% supervision, 3 x 20 min training initial instructions
C: Arm Label: Cognitive and physical program; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive, Relaxation, Exercise Therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive, Relaxation, Exercise Therapy; Assigned to Arm(s): Cognitive and physical program
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: spinal manipulation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: Spinal manipulation + exercises | Intervention Type: OTHER; Name: spinal manipulation; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Spinal manipulation + exercises; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety in Obese Patients With Type 2 Diabetes
Brief Summary: To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with Type 2 Diabetes


Options:
A: Arm Label: Lorcaserin 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg BID | Arm Label: Matching Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo BID | Intervention Type: DRUG; Name: Lorcaserin 10 mg BID; Assigned to Arm(s): Lorcaserin 10 mg BID | Intervention Type: DRUG; Name: Matching Placebo BID; Assigned to Arm(s): Matching Placebo BID
B: Arm Label: NB32; Type: EXPERIMENTAL; Interventions: Drug: NB32, Behavioral: Weight Management Program | Arm Label: PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: PBO, Behavioral: Weight Management Program | Intervention Type: DRUG; Name: NB32; Assigned to Arm(s): NB32 | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): PBO | Intervention Type: BEHAVIORAL; Name: Weight Management Program; Assigned to Arm(s): NB32, PBO
C: Intervention Type: DRUG; Name: Rimonabant (SR141716); Assigned to Arm(s): N/A
D: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety in Obese Patients With or Without Comorbidities
Brief Summary: To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities


Options:
A: Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo
B: Arm Label: Lorcaserin hydrochloride (HCL)10 mg; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lorcaserin hydrochloride; Assigned to Arm(s): Lorcaserin hydrochloride (HCL)10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VI-0521 Mid; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Arm Label: VI-0521 Top; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Mid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Top
D: Intervention Type: DRUG; Name: Rimonabant (SR141716); Assigned to Arm(s): N/A

Answer: D